AXGN vs. STOK
AXGN (AxoGen, Inc.) and STOK (Stoke Therapeutics, Inc.) are both stocks. Both are in the Healthcare sector — AXGN in Medical Devices, STOK in Biotechnology. Over the past 5 years, AXGN returned 18.83%/yr vs 2.06%/yr for STOK. Their 0.28 correlation means their historical movements had little consistent relationship.
Performance
AXGN vs. STOK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, AXGN achieves a 39.72% return, which is significantly higher than STOK's -6.87% return.
AXGN
- 1D
- 8.34%
- 1M
- -0.35%
- 6M
- 30.58%
- YTD
- 39.72%
- 1Y
- 260.93%
- 3Y*
- 75.78%
- 5Y*
- 18.83%
- 10Y*
- 18.28%
- ALL TIME*
- 7.01%
STOK
- 1D
- 2.43%
- 1M
- -9.60%
- 6M
- -3.93%
- YTD
- -6.87%
- 1Y
- 128.97%
- 3Y*
- 69.04%
- 5Y*
- 2.06%
- 10Y*
- —
- ALL TIME*
- 1.17%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
AXGN AxoGen, Inc. | $52.56M | $54.51M | $52.29M |
| $25.25M | $22.28M | $23.90M |
AXGN vs. STOK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
AXGN AxoGen, Inc. | 39.72% | 98.60% | 141.29% | -31.56% | 6.51% | -47.65% | 0.06% | -8.40% |
STOK Stoke Therapeutics, Inc. | -6.87% | 187.76% | 109.70% | -43.01% | -61.53% | -61.26% | 118.68% | 4.08% |
Correlation
The correlation between AXGN and STOK is 0.18, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.18 |
Correlation (3Y) Balances recent behavior with more history. | 0.24 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.29 |
Correlation (All Time) Calculated using the full available price history since Jun 19, 2019 | 0.28 |
The correlation between AXGN and STOK shifts across timeframes, from 0.18 (1 year) to 0.29 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
AXGN:
$2.46B
STOK:
$1.84B
AXGN:
-$0.68
STOK:
-$3.38
AXGN:
9.00
STOK:
65.92
AXGN:
9.52
STOK:
5.65
AXGN:
$251.17M
STOK:
$27.59M
AXGN:
$187.27M
STOK:
$15.17M
AXGN:
-$14.77M
STOK:
-$206.50M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AXGN vs. STOK — Risk / Return Rank
AXGN
STOK
AXGN vs. STOK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for AxoGen, Inc. (AXGN) and Stoke Therapeutics, Inc. (STOK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AXGN | STOK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.80 | ||
| Sortino ratioReturn per unit of downside risk | +2.07 | ||
| Omega ratioGain probability vs. loss probability | 1.61 | 1.35 | +0.26 |
| Calmar ratioReturn relative to maximum drawdown | 13.61 | 3.49 | +10.12 |
| Martin ratioReturn relative to average drawdown | 40.64 | 8.82 | +31.82 |
Loading charts...
Drawdowns
AXGN vs. STOK - Drawdown Comparison
The maximum AXGN drawdown since its inception was -98.49%, roughly equal to the maximum STOK drawdown of -95.17%. Use the drawdown chart below to compare losses from any high point for AXGN and STOK.
Loading charts...
Drawdown Indicators
| AXGN | STOK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.49% | -95.17% | -3.32% |
Max Drawdown (1Y)Largest decline over 1 year | -19.30% | -37.16% | +17.86% |
Max Drawdown (3Y)Largest decline over 3 years | -57.13% | -66.32% | +9.19% |
Max Drawdown (5Y)Largest decline over 5 years | -81.35% | -89.03% | +7.68% |
Max Drawdown (10Y)Largest decline over 10 years | -93.54% | — | — |
Current DrawdownCurrent decline from peak | -18.19% | -57.66% | +39.47% |
Average DrawdownAverage peak-to-trough decline | -64.71% | -62.15% | -2.56% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.45% | 14.68% | -8.23% |
Volatility
AXGN vs. STOK - Volatility Comparison
AxoGen, Inc. (AXGN) has a higher volatility of 14.40% compared to Stoke Therapeutics, Inc. (STOK) at 12.49%. This indicates that AXGN's price experiences larger fluctuations and is considered to be riskier than STOK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AXGN | STOK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.40% | 12.49% | +1.91% |
Volatility (6M)Calculated over the trailing 6-month period | 34.65% | 35.83% | -1.18% |
Volatility (1Y)Calculated over the trailing 1-year period | 54.40% | 63.66% | -9.26% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 64.35% | 80.70% | -16.35% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 61.87% | 79.73% | -17.86% |
Dividends
AXGN vs. STOK - Dividend Comparison
Neither AXGN nor STOK has paid dividends to shareholders.
Financials
AXGN vs. STOK - Financials Comparison
This section allows you to compare key financial metrics between AxoGen, Inc. and Stoke Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
AXGN and STOK have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AXGN has higher volatility (14.40%) compared to STOK (12.49%). In terms of maximum drawdown, AXGN dropped -98.49% vs STOK's -95.17%.
AXGN currently has the higher Sharpe Ratio (4.84 vs 2.04), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for AXGN and STOK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer